王杭祥附属第一医院 | 医学院临床医学药物递送，肿瘤药物研发及分子机制研究个人简介:学习经历：2002年本科毕业于浙江大学材料与化学工程学院，期间被选派至日本福井大学材料开发工学部交换留学1年。2006年获大阪大学(日本)工学研究科分子化学专业硕士学位。2010年毕业于京都大学(日本)工学研究科合成生物化学专业，获工学博士学位。工作经历：浙江大学医学院博士后(2011.3-2014.1)助理研究员(2011.6-2014.12)副研究员(2015.1-)现为浙江大学医学院附属第一医院卫生部多器官联合移植研究重点实验室PI，博士生导师。谷歌学术个人主页：https://scholar.google.com/citations?user=8NI3ykwAAAAJ&hl=en&oi=aoMyORCID: http://orcid.org/0000-0001-6370-9728实验室长期招聘博士后研究人员，待遇从优。有兴趣的同学请跟我联系。 代表性论文：1)  J. Wan Y. Qiao X. Chen J. Wu L. Zhou J. Zhang S. Fang and H. Wang* Adv. Funct. Mater. 2018 In press.   2) H. Wang* Z. Lu L. Wang T. Guo J. Wu Z. Li D. Jiang P. Song H. Xie L. Zhou X. Xu and S. Zheng* New Generation Nanomedicines Constructed from Self-Assembling Small Molecule Prodrugs Alleviate Cancer Drug Toxicity Cancer Research 2017 77 6963-6974. 3)     H. Wang H. Xie J. Wu X. Wei L. Zhou X. Xu* and S. Zheng* Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery Platforms for enhanced antitumor efficacy Angew. Chem. Int. Ed. 2014 53 11532-11537. 4)     H. Wang Y. Koshi D. Minato H. Nonaka S Kiyonaka Y. Mori S. Tsukiji and I. Hamachi* Chemical cell-surface receptor engineering using affinity-guided multivalent organocatalysts J. Am. Chem. Soc. 2011 133 12220-12228. 5)     H. Wang H. Xie J. Wang J. Wu X. Ma L. Li X. Wei Q. Ling P. Song L. Zhou X. Xu* and S. Zheng* Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability pharmacokinetics and antitumor efficacy Adv. Funct. Mater. 2015 25 4956-4965. 6)     R. Lei J. Hou Q. Chen W. Yuan B. Cheng Y. Sun Y. Jin L. Ge S. A. Ben-Sasson H. Wang* W. Lu* X. Fang* Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection ACS Nano 2018 12 5284-5296. 7)     G. Chen* J. Chen Y. Qiao Y. Shi W. Liu Q. Zeng X. Shi Y. Sun X. Liu T. Li L. Zhou J. Wan H. Wang* and F. Wang* ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination Repair Nucleic Acids Res. 2018 46 1266-1279. 8)     H. Wang* L. Zhou K. Xie J. Wu P. Song H. Xie L. Zhou J. Liu X. Xu Y. Shen and S. Zheng* Polyactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma Theranostics 2018 8 3949-3963. 9)     H. Wang* J. Chen C. Xu M. Tayier J. Zhou J. Zhang J. Wu Z. Ye T. Fang W. Han* Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations Theranostics 2017 7 3638-3652. 10)     T. Fang Z. Ye J. Wu and H. Wang* Reprogramming Axial Ligands Facilitates the Self-Assembly of a Platinum(IV) Prodrug: Overcoming Drug Resistance and Safer in Vivo Delivery of Cisplatin Chem. Commun. 2018 54 9167-9170. 11)   H. Wang* J. Wu L. Xu K. Xie C. Chen and Y. Dong* Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity Chem. Commun. 2017 53 2618-2621. 12)   H. Xie X. Xu J. Chen L. Li J. Wang T. Fang L. Zhou H. Wang* S. Zheng Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo Chem. Commun. 2016 52 5601-5604. 13)   H. Wang Wei Chen H. Xie X. Wei S. Yin L. Zhou X. Xu* and S. Zheng* Biocompatible chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing Chem. Commun. 2014 50 7806-7809. 14)   L. Xu S. Xu H. Wang* J. Zhang Z. Chen L. Pan J. Wang X. Wei H. Xie L. Zhou S. Zheng and X. Xu* Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: the Combination of Polymeric Prodrug Design Nanoparticle Encapsulation and Cancer Cell-Specific Drug Targeting ACS Appl. Mater. Interfaces 2018 10 3229-3240. 15)   H. Wang* J. Wu K. Xie T. Fang* C. Chen H. Xie. L. Zhou and S. Zheng* Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extented and Sequentially Controllable Drug Release ACS Applied Materials & Interfaces 2017 9 10567-10576. 16)   J. Wang H. Wang* J. Li Z. Liu H. Xie X. Wei D. Lu R. Zhuang X. Xu* and S. Zheng* iRGD-decorated polymeric nanoparticles for the efficient delivery of vandetanib to hepatocellular carcinoma: preparation and in vitro and in vivo evaluation ACS Appl. Mater. Interfaces 2016 8 19228-19237.实验室介绍:化学药物治疗(化疗)是临床上恶性肿瘤最主要的治疗方式之一。然而、药物在肿瘤部位靶向性差，积蓄浓度低，多次给药产生的系统性毒性等因素往往导致临床化疗的失败。为解决上述局限，课题组从化疗药物的结构改性和分子自组装技术入手，构建了一系列具有自组装能力的小分子和聚合物前药，有效提高了细胞毒药物的临床使用价值。主要研究成果：利用药物小分子的自组装技术制备绿色环保型型纳米药物，降低药物的作用。课题组提出长链不饱和脂肪酸可用于疏水性药物的衍生化，并发现水溶性极差的卡巴他赛(紫杉醇的同族衍生物)经不饱和脂肪酸如DHA修饰后具备在水溶液中自组装形成超分子纳米结构的能力。自组装药物在体内水解释放出卡巴他赛及DHA，而DHA又是为人体所必需。该技术有效规避了药物在临床应用时需要使用吐温80及乙醇等助溶剂而带来的毒性问题。通过大量的动物实验表明卡巴他赛的体内副作用被极大地降低。研究成果发表于肿瘤学期刊Cancer Research (2017 77 6963-6974)。继而，课题组发现DHA的药物衍生法仍适用于喜树碱类药物及顺铂的无溶剂型绿色纳米制剂的构建，上述研究成果分别发表于Adv. Funct. Mater. (2015 25 4956-4965)和Chem. Commun. (2018 549167-9170)。 利用小分子的二聚体技术，构建自组装型细胞毒药物纳米颗粒。课题组利用小分子药物偶联物之间的π-π相互作用，构建具有高稳定性和高载药量(>92%)的超分子自组装型纳米药物。体内动物实验论证了该技术不仅提高了联用药物的体内安全性，并显示出有效的药物协同作用。该项研究成果发表于生物医学领域期刊Theranostics (2017 7 3638-3652)。上述偶联物前药的化学结构明确，同时自组装技术构建的纳米药物制备过程简单。相比聚合物载药体系，制备批次之间的稳定性较好，具有较好的临床转化前景。 提出抗癌药物活性分子改造技术与高分子载药系统相结合的新概念，显著提升现有抗癌活性分子的体内抑瘤效果。大部分抗肿瘤化疗药物的水溶性极差，严重限制了其临床应用。课题组成功开发出抗癌药物分子前药设计与聚合物载药相融合的新技术，有效提升了SN38的临床应用价值。该研究发表于Angew. Chem. Int. Ed. (2014 53 11532-11537)。课题组进一步地优化了前药设计，开发了第二和第三代稳定性更佳，体内效果更优，副作用更低的SN38纳米药物版本，并发现该纳米药物在肝癌病人组织的移植瘤模型中具有非常优异的抑瘤效果。上述论文分别发表于ACS App. Mater. & Interfaces (2017 9 10567-10576)和生物医学领域期刊Theranostics (2018 8 3949-3963)。发表论文:2019 37 TBAK. Xie L. Zhou J. Wan Y. Qiao M. Wang H. Xie L. Zhou S. Zheng* and H. Wang*International Journal of Pharmaceutics In revision. 36 Rhodium-Catalyzed Annulation of α-Imino Carbenes with αβ-Unsaturated Ketones: Construction of Multi-substituted 23-Dihydropyrrole/pyrrole RingsX. Ma L. Liu J. Wang X. Xi X. Xie H. Wang*The Journal of Organic Chemistry In press. 35 Structure-guided engineering of cytotoxic cabazitaxel for an adaptive nanoparticle formulation: Enhancing the drug safety and therapeutic efficacyJ. Wan Y. Qiao X. Chen J. Wu L. Zhou J. Zhang S. Fang and H. Wang*Adv. Funct. Mater. 2018 1804229 (IF:13.325).  2018 34 Chemical derivatization of the anticancer agent cabazitaxel using a polyunsaturated fatty acid for safe drug delivery in vivoZ. Lu T. Li L. Zhou J. Wan J. Wu Y. Qiao H. Xie S. Zheng* and H. Wang*J. Biomed. Nanotechnol. 2018 14 1853-1865 (IF:5.068). 33 Reprogramming axial ligands facilitates the self-assembly of a platinum(IV) prodrug: Overcoming drug resistance and safer in vivo delivery of cisplatinT. Fang Z. Ye J. Wu and H. Wang*Chem. Commun. 2018 54 9167-9170 (IF:6.29). 32 Silver nanoparticles for enhanced cancer theranostics: in vitro and in vivo perspectivesY. Li Y. Chang X. Lian L. Zhou Z. Yu H. Wang* F. An*J. Biomed. Nanotechnol. 2018 14 1515-1542 (IF:5.068). 31 Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinomaH. Wang* L. Zhou K. Xie J. Wu P. Song H. Xie L. Zhou J. Liu X. Xu Y. Shen and S. Zheng*Theranostics 2018 8 3949-3963 (IF:8.537). 30 Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infectionR. Lei J. Hou Q. Chen W. Yuan B. Cheng Y. Sun Y. Jin L. Ge S. A. Ben-Sasson H. Wang* W. Lu* X. Fang*ACS Nano 2018 12 5284-5296 (IF:13.709). 29 A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancerW. Han L. Shi T. Li L. Zhou L. Ren Y. Qiao and H. Wang*Signal Transduction and Targeted Therapy 2018 3 16. 28 Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapyY. Qiao J. Wan L. Zhou W. Ma Y. Yang Z. Yu and H. Wang*WIREs Nanomed. Nanobiotechnol. Online published (IF:6.35). 27 Facile one-pot nanocatalysts encapsulation of palladium-NHC complexes for aqueous Suzuki-Miyaura couplingC. Chen* Q. Zheng S. Ni and H. Wang*New J. Chem. 2018 42 4624-4630 (IF:3.201). 26 The Hippo pathway as a drug target in gastric cancerY. Qiao T. Li S. Zheng* and H. Wang*Cancer Letters 2018 420 14-25 (IF:6.375). 25 Facile Synthesis of Pyrroloindoles via a Rhodium(II)-Catalyzed Annulation of 3-Benzylidene-indolin-2-ones and α-Imino CarbenesX. Ma G. Feng L. Zhou L. Wei K. Xie and H. Wang*Chem. Commun. 2018 54 1595-1598 (IF:6.29). 24 Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: the Combination of Polymeric Prodrug Design Nanoparticle Encapsulation and Cancer Cell-Specific Drug TargetingL. Xu S. Xu H. Wang* J. Zhang Z. Chen L. Pan J. Wang X. Wei H. Xie L. Zhou S. Zheng and X. Xu*ACS Appl. Mater. Interfaces 2018 10 3229-3240 (IF:8.097). 23 ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination RepairG. Chen* J. Chen Y. Qiao Y. Shi W. Liu Q. Zeng X. Shi Y. Sun X. Liu T. Li L. Zhou J. Wan H. Wang* and F. Wang*Nucleic Acids Res. 2018 46 1266-1279 (IF:11.163).  2017 22 New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug ToxicityH. Wang* Z. Lu L. Wang T. Guo J. Wu Z. Li D. Jiang P. Song H. Xie L. Zhou X. Xu and S. Zheng*Cancer Res. 2017 77 6963-6974 (IF:9.13). 21 Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug CombinationsH. Wang* J. Chen C. Xu M. Tayier J. Zhou J. Zhang J. Wu Z. Ye T. Fang W. Han*Theranostics 2017 7 3638-3652 (IF:8.537). 20 Self-Emulsifying Hydrophobic Prodrug Conjugate That Enables the Oral Co-Administration and Programmable Release of Dual Antitumor DrugsL. Wang Q. Chen J. Wu J. Wan L. Zhou L. Zhao Z. Yu* and H. Wang*J. Biomed. Nanotechnol. 2017 13 1260-1271 (IF:5.068). 19 Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extented and Sequentially Controllable Drug ReleaseH. Wang* J. Wu K. Xie T. Fang* C. Chen H. Xie. L. Zhou and S. Zheng*ACS App. Mater. & Interfaces 2017 9 10567-10576 (IF:8.097). 18 A Facile Supramolecular Approach to Fabricate Multifunctional Upconversion Nanoparticles as a Versatile Platform for Drug Loading in Vivo Delivery and Tumor ImagingY. Yuan L. Xu S. Dai M. Wang* and H. Wang*J. Mater. Chem. B 2017 5 2425-2435 (IF:4.776). 17 Albumin Nanoparticle Encapsulation of Potent Cytotoxic Therapeutics Shows Sustained Drug Release and Alleviates Cancer Drug ToxicityH. Wang* J. Wu L. Xu K. Xie C. Chen and Y. Dong*Chem. Commun. 2017 53 2618-2621 (IF:6.29). 16 Synthesis Structure Biological Evaluation and Catalysis of Two Pyrazole-Functionalized NHC-Ru(II) ComplexesC. Chen* J. Liu S. Ni Q. Zheng M. Yu and H. Wang*Eur. J. Inorg. Chem. 2017 3 616-622 (IF:2.507).  2016 15 Intergrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumorsT. Fang Y. Dong X. Zhang K. Xie L. Lin and H. Wang*Int. J. Pharmaceut. 2016 512 39-48 (IF:3.994). 14 iRGD-decorated polymeric nanoparticles for the efficient delivery of vandetanib to hepatocellular carcinoma: preparation and in vitro and in vivo evaluationJ. Wang H. Wang* J. Li Z. Liu H. Xie X. Wei D. Lu R. Zhuang X. Xu* and S. Zheng*ACS Applied Materials & Interfaces 2016 8 19228-19237 (IF:7.145). 13 Rational Design of Multifunctional Small-Molecule Prodrugs for Simultaneous Suppression of Cancer Cell Growth and Metastasis in Vitro and in VivoH. Xie X. Xu J. Chen L. Li J. Wang T. Fang L. Zhou H. Wang* S. ZhengChem. Commun. 2016 52 5601-5604 (IF:6.834).  2015 12 Self-Assembling Prodrugs by Precise Programming of Molecular Structures that Contribute Distinct Stability Pharmacokinetics and Antitumour EfficacyH. Wang H. Xie J. Wang J. Wu X. Ma L. Li X. Wei Q. Ling P. Song L. Zhou X. Xu* S. Zheng*Adv. Funct. Mater. 2015 25 4956-4965 (IF:11.805). 11 One-pot synthesis of 23-disubstituted dihydrobenzofurans and benzofurans via rhodium-catalyzed intramolecular C-H insertion reactionX. Ma F. Wu X. Yi H. Wang* W. Chen*Chem. Commun. 2015 51 6862-6865 (IF:6.718).  2014 10 Structure-Based Rational Design of Prodrugs to Enable Their Combination with Polymeric Nanoparticle Delivery Platforms for Enhanced Antitumor EfficacyH. Wang H. Xie J. Wu X. Wei L. Zhou X. Xu* S. Zheng*Angew. Chem. Int. Ed. 2014 53 11532-11537 (IF:11.336). 9 Rhodium-Catalyzed Transannulation of N-Sulfonyl-123-triazoles and Epoxides: Regioselective Synthesis of Substituted 34-Dihydro-2H-14-OxazinesX. Ma S. Pan H. Wang* W. Chen*Org. Lett. 2014 16 4554-4557 (IF:6.324). 8 N-Heterocyclic Carbene-Stabilized Palladium Complexes as Efficient Organometallic Catalysts for Bioorthogonal Cross-Coupling ReactionsX. Ma H. Wang* W. Chen*J. Org. Chem. 2014 79 8652-8658 (IF:4.638). 7 Deoxycholic Acid-Modified Chitooligosaccharide/mPEG-PDLLA Mixed Micelles Loaded with Paclitaxel for Enhanced Antitumor EfficacyC. Jiang# H. Wang#* X. Zhang Z. Sun F. Wang J. Cheng H. Xie B. Yu* L. Zhou*Int. J. Pharmaceut. 2014 475 60-68 (#contributed equally) (IF:3.785). 6 Biocompatible Chimeric Peptide-Condensed Supramolecular Nanoparticles for Tumor Cell-Specific siRNA Delivery and Gene SilencingH. Wang W. Chen H. Xie X. Wei S. Yin L. Zhou X. Xu* S. Zheng*Chem. Commun. 2014 50 7806-7809 (IF:6.718).  Before ZJU 5 Chemical Cell-Surface Receptor Engineering Using Affinity-Guided Multivalent OrganocatalystsH. Wang Y. Koshi D. Minato H. Nonaka S. Kiyonaka Y. Mori S. Tsukiji I. Hamachi*J. Am. Chem. Soc. 2011 133 12220-12228 (IF:11.444). 4 Quenched Ligand-Directed Tosylate Reagents for One-Step Construction of Turn-On Fluorescent BiosensorsS. Tsukiji H. Wang M. Miyagawa T. Tamura Y. Takaoka I. Hamachi*J. Am. Chem. Soc. 2009 131 9046-9054 (IF:11.444). 3 Recent Progress in Strategies for the Creation of Protein-Based Fluorescent BiosensorsH. Wang E. Nakata I. Hamachi*ChemBioChem 2009 10 2560-2577 (IF:3.06). 2 Ratiometric Fluorescent Biosensor for Real-Time and Label-Free Monitoring of Fine Saccharide Metabolic PathwaysE. Nakata H. Wang I. Hamachi*ChemBioChem 2008 9 25-28 (IF:3.06). 1 Pyrene-Stacked Nanostructures Constructed in the Recombinant Tobacco Mosaic Virus Rod ScaffoldM. Endo* H. Wang M. Fujitsuka T. Majima*Chemistry-A European Journal 2006 12 3735-3740 (IF:5.696).专利成果:25 顺铂纳米药物制剂、制备方法和应用，申请号：201810790048524 顺铂药物前体、制备方法和应用，申请号：201810790106423 两亲性聚合物包裹的吉非替尼和环孢素A纳米颗粒、制备方法及应用，申请号：201710840265.622，一种制备吡咯并吲哚类衍生物的方法，申请号：201710840158.321，一种制备14-氧氮杂卓并吲哚类衍生物的方法，申请号：201710839849.120，一种集荧光成像与载药一体化的稀土上转换纳米药物载体及其应用，申请号：201710001962.219，一种集荧光成像与载药一体化的稀土上转换纳米药物载体的制备方法，申请号：2017100012330.818，阿司匹林紫杉醇抗癌药物偶联物、合成方法及其应用，申请号：201611030474617，阿司匹林抗癌药物偶联物、合成方法及其应用，申请号：201611030369216，7-乙基-10-羟基喜树碱-聚合物偶联药物及其纳米制剂制备方法，申请号：201610959750.015，两亲性共聚物-美登素类共价偶联药物、制备方法及应用，申请号：201610873706.814，一种具有抗癌活性的吡唑官能团化的氮杂环卡宾钌化合物及其制备方法和应用，申请号：201610902563.913，康普瑞汀药物前体、药物制剂和制备方法，申请号：201610621678012，联合用药抗肿瘤药物、制备方法及应用，申请号：201610613652.111，卡巴他赛药物前体的制备方法和应用，申请号：201610576126.210，一种人血清白蛋白负载喜树碱类药物的纳米颗粒及其制备方法和应用，申请号：201610496426.X9，一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用，申请号：201610493755.98，一种iRGD-抗癌药物偶联物及其制备方法和应用，申请号：201510917850.27，iRGD-抗癌药物偶联物及其制备方法和应用，申请号：201510915139.36，一种抗肿瘤药物偶联物、制备方法、制剂和应用，申请号：201610700195X 授权号：ZL201610700195.X5，一种全反式维甲酸-喜树碱类抗癌药物偶联物及其制备方法和应用，申请号：201410692682.7，授权号：ZL201410692682.74，一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用，申请号：201410692283.0，授权号：ZL201410692283.03，7-乙基-10羟基喜树碱药物前体及其制备方法和应用，申请号：201410295432X 授权号：ZL201410295432.X2，一种紫衫烷类药物前体，申请号：201410031867.3，授权号：ZL201410031867.31， 一种多肽及包含该多肽的核酸药物，授权号：ZL201410031237.6工作研究项目:1）项目负责人，在研，国家自然科学基金面上项目：克服三阴性乳腺癌耐药的共输送载药系统的筛选及基于PDX模型的治疗价值研究 2018.1-2021.12；2）项目负责人，在研，国家自然科学基金面上项目：基于小分子前药的联合化疗纳米药物的筛选及抗肝癌的机制研究 2016.1-2019.12；3)  项目负责人，在研，浙江省自然科学基金杰出青年项目：肝癌精准靶向的纳米药物及应用研究 2019.1-2022.12；4）子任务负责人，在研，国家科技重大专项：艾滋病和病毒性肝炎等重大传染病防治 2017.1-2020.12；5）项目负责人，已结题，国家自然科学青年基金：基于病毒衣壳蛋白的光可控纳米载药系统的构建及靶向抗肿瘤应用研究 2013.1-2015.12；6）已结题，国家高技术研究发展计划(863计划)：肝病发生发展与肝癌转移复发的蛋白质分子标志物的临床应用研究 2012.1-2015.12 (作为课题骨干参与)；7）已结题，浙江省重大科技专项：新型纳米材料靶向输送技术的研发及在肝癌治疗中的应用研究 2015.1-2017.12 （2/10）。